Kangaroo bonds are Australian dollar bonds sold by foreignborrowers in Australia The increase brings new total size to A$1

Kangaroo bonds are Australian dollar bonds sold by foreignborrowers in Australia The increase brings new total size to A$1.4 billion. Themargin is equivalent to 109 basis points over the 2012Australian government bond KfW is rated triple A by all major ratings agencies. ($1=1.419 Australian Dollar) (Reporting by Cecile Lefort; Editing by Mark Bendeich). GOETTINGEN, Germany--(Business Wire)--Regulatory News: ? in millions March 2009March 2008Growth in %Growth in %, Unaudited figuresconst. currenciesSales revenue 96.891.3+6.1%+3.6%? Europe1)57.058.1-2.0%-0.1%? North America1) 23.719.2+23.5% +7.7%? Asia - Pacific1)12.111.3+7.5%+4.5%? Other Markets1) 4.0 2.6 +50.7% +50.7% EBITA 12.69.4 EBITA margin13.0% 10.3% Net profit2)6.6 4.61) According to customers` location 2) Excluding amortization Dynamic start into fiscal 2009, especially in the U.S.In the first quarter of 2009, Sartorius Stedim Biotech (SSB)(Paris:DIM) achievedsignificant growth in order intake and sales. This was especially driven by thestrong double-digit gains of its high-margin single-use products forbiopharma-ceutical applications.

Compared with the strong year-earlier quarter,the more volatile equipment business was weaker. Regional assessment shows thatSSB posted its highest growth rates in North America, where the marketconditions have substantially improved since the fourth quarter of 2008. Profitability increases overproportionatelyAs a result of economies of scale, a more profitable product mix and bettercurrency exchange rates, Sartorius Stedim Biotech significantly boosted itsearnings margin from 10.3% to 13.0%. Net profit after minority interest andexcluding amortization totaled ?6.6 million, up from ?4.6 million a year ago.

Strong financial positionReflected by an equity ratio of 57.7% and a gearing of 0.4, the financialposition of the Sartorius Stedim Biotech Group further enhanced its very robustlevel. Positive outlookWith the company`s performance confirmed by its strong first-quarter results,management expects revenue growth and an overproportionate increase of earningsin the current year. However, in view of the ongoing high uncertainty regardingthe global economy, management still does not consider it possible to make aprecise quantitative forecast about SSB's business development in 2009. This press release contains statements about the future development of theSartorius Stedim Biotech Group.

We cannot guarantee that the content of thesestatements will actually apply because these statements are based uponassumptions and estimates that harbor certain risks and uncertainties. Conference Call and WebcastJoachim Kreuzburg, CEO and Chairman of the Board of the Sartorius Stedim BiotechGroup, will discuss the results with analysts and investors on Thursday, April23, 2009, at 4:30 p.m Central European Time (CET), in a teleconference You maydial into the teleconference starting at 4:15 p.m. CET at the followingnumbers: Germany: +49 (0)69 2222 2245 France: +33 (0)1 70 99 42 77 UK: +44 (0)20 7138 0826USA: +1 212 444 0481The dial-in code is: 4627574 To view the webcast or presentation, log onto: profile of Sartorius Stedim BiotechSartorius Stedim Biotech is a leading provider of cutting-edge equipment andservices for the development, quality assurance and production processes of thebiopharmaceutical industry. Its integrated solutions covering fermentation,filtration, purification, fluid management and lab technologies are supportingthe biopharmaceutical industry around the world to develop and produce drugssafely, timely and economically. For next generation processes, Sartorius StedimBiotech focuses on single-use technologies and value-added services to meet therapidly changing technology requirements of the industry it serves. Stronglyrooted in the scientific community and closely allied with customers andtechnology partners, the company is dedicated to its philosophy of "turningscience into solutions" on a daily basis. Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on theEurolist of Euronext Paris.

With its own manufacturing and R&D sites in Europe,North America and Asia and a global network of sales companies, Sartorius StedimBiotech enjoys a worldwide presence Its key manufacturing and R&D site is inGermany. The company employs over 2,300 people, and in 2008 generated salesrevenue of 368.0 million euros. Sartorius Corporate Administration GmbHPetra Kirchhoff; Vice President of CommunicationsPhone: +49(0)551/ 308-1686Fax: +49(0)551/ 308-3410e-mail: http:// orPress-Service: http:// Business Wire 2009. HONG KONG, April 23 (Reuters) - China COSCO (1919.HK)(601919.SS) said on Thursday it would cut capital spending by 29percent in 2008 and was in talks to delay or cancel some new shiporders, after posting a worse-than-expected second half loss. The world's largest dry bulk ship operator said it hadearmarked 14.4 billion yuan ($2.11 billion) for capitalexpenditure in 2008 against 20.3 billion a year earlier. Capital commitment for vessels was at 32.03 billion yuan asthe end of 2008, of which container ships accounted for 17.4billion yuan and dry bulk vessels 14.6 billion yuan, it said inresults presentations. China COSCO said it was in talks with shipyards to delay thedelivery of or cancel some new dry bulk vessel orders due tonegative market conditions (Reporting by Joanne Chiu; Editing by Jonathan Hopfner).